Hikma Pharmaceuticals Regulatory News (HIK)

21 Nov 2007 15:56

Hikma Pharmaceuticals Plc21 November 2007 Update on lisinopril contract London, 21 November 2007 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)("Hikma") announces that it is still awaiting the re-issuance of thesolicitation for the supply of lisinopril from the US Department of VeteransAffairs. Once this solicitation is issued, Hikma intends to participate asnormal in the bidding process. Hikma continues to supply lisinopril under itsexisting contract with the Department of Veterans Affairs, which runs through to20 December 2007. - ENDS - Enquiries: Hikma Pharmaceuticals PLC +44 20 7399 2670Susan Ringdal, Investor Relations Director Brunswick Group LLP +44 20 7404 5959Jon Coles / Justine McIlroy / Alex Tweed Notes to Editors About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed products. Hikma operates through threebusinesses: "Branded", "Injectables" and "Generics", based principally in theMiddle East and North Africa ("MENA"), where it is a market leader and sellsacross 18 countries, the United States and Europe. In the year ended 31December 2006, Hikma achieved revenues of $317 million (2005: $262 million) andprofit attributable to shareholders was $55 million (2005: $44 million). At 31December 2006, the Group had over 2,400 employees. For news and otherinformation, please visit www.hikma.com This information is provided by RNS The company news service from the London Stock Exchange